CREX
Creative Realities, Inc.
CREX's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over CREX overall, supported by stronger fundamentals and stronger valuation.
CREX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Stable |
CREX's revenue is currently strong, and its balance sheet is stable, but its profitability and cash flow are weak.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CREX PE Valuation
CREX has no meaningful PE right now: it lost money over the past year.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
CREX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
CREX has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CREX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.11 | -$1.99 |
| Q1 2026 | -$1.87 | -$1.86 |
| Q4 2025 | -$0.81 | -$0.47 |
| Q3 2025 | -$0.88 | -729% |
| Q2 2025 | -$0.12 | -$0.03 |
| Q1 2025 | -$0.01 | +$0.21 |
| Q4 2024 | -$0.34 | +$0.01 |
| Q3 2022 | $0.15 | -55% |
CREX is still losing money, but far less than before: $2.11 per share over the past year, against $5.16 at its worst in late 2020.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CREX on earnings quality, reporting a profit while its opponent remains loss making.
CREX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $21.5M | +65% |
| Q1 2026 | $16.3M | +68% |
| Q4 2025 | $23.9M | +117% |
| Q3 2025 | $10.5M | -27% |
| Q2 2025 | $13M | -0.6% |
| Q1 2025 | $9.7M | -21% |
| Q4 2024 | $11M | -24% |
| Q3 2024 | $14.4M | +25% |
CREX's revenue is recovering but still below its 2022 peak: $22M last quarter, up 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -13% | -2.5 points |
| Q1 2026 | -38% | -31 points |
| Q4 2025 | 1.9% | +8.4 points |
| Q3 2025 | -69% | -77 points |
| Q2 2025 | -10% | -15 points |
| Q1 2025 | -7.4% | -6.8 points |
| Q4 2024 | -6.5% | -20 points |
| Q3 2024 | 7.9% | +6.5 points |
CREX's operating margin was −13% last quarter, down 2.5 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CREX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CREX on profitability, with a higher operating margin.
CREX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $457K | -32% |
| Q1 2026 | -$1.9M | +$551K |
| Q4 2025 | -$7M | -$5.6M |
| Q3 2025 | -$1.7M | -415% |
| Q2 2025 | $672K | -70% |
| Q1 2025 | -$2.5M | -227% |
| Q4 2024 | -$1.4M | +$1.8M |
| Q3 2024 | $543K | -71% |
CREX's free cash flow was −$10M over the past year, against −$3M the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CREX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CREX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +16K shares |
| 1 year | +1.2% | +121K shares |
| 3 years | +44% | +3.2M shares |
| 5 years | +211% | +7.2M shares |
CREX has 11M diluted shares, up 1.2% from a year ago.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over CREX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CREX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | 2.1x | Moderate |
| Q4 2023 | 2.3x | Moderate |
| Q3 2023 | 4.8x | High |
| Q2 2023 | 13.2x | High |
| Q1 2023 | 10.0x | High |
| Q4 2022 | 45.2x | High |
| Q4 2019 | 4.9x | High |
CREX's net debt is about 2.1 years of its operating earnings (EBITDA), down from 10 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CREX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 8.9 | Oversold |
CREX's weekly RSI is 33 (neutral) and its Stochastic is 9 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CREX PE vs Technology Sector
| Metric | CREX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
CREX has no meaningful PE right now: it lost money over the past year.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CREX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.25 | 4.4% below |
| 20 week MA | $2.79 | 23% below |
| 50 week MA | $3.20 | 33% below |
| 100 week MA | $2.87 | 25% below |
| 200 week MA | $2.98 | 28% below |
CREX is in a downtrend: it's below all five of its weekly moving averages, and 28% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has the edge over CREX on trend strength, trading above more of its moving averages.
CREX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.20 | $3.90 | -7.1% |
| 2021 | $3.90 | $4.38 | +12% |
| 2022 | $4.38 | $1.71 | -61% |
| 2023 | $1.71 | $2.36 | +38% |
| 2024 | $2.36 | $2.69 | +14% |
| 2025 | $2.69 | $2.66 | -1.1% |
| 2026 YTD | $2.66 | $2.15 | -19% |
CREX has finished lower in three of the last six years. It's down 19% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over CREX on returns for 2026, with the stronger performance.